Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

42.9%

3 terminated/withdrawn out of 7 trials

Success Rate

40.0%

-46.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
3(50.0%)
Phase 1
3(50.0%)
6Total
Phase 2(3)
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT05476783Phase 2Terminated

A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease

Role: lead

NCT06773962Phase 2Active Not Recruiting

A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease

Role: lead

NCT04920786Phase 1Completed

Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects

Role: lead

NCT05959239Unknown

TB006 Expanded Access (EA) Compassionate Use

Role: lead

NCT05156827Phase 2Withdrawn

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of TB006 in Participants With Acute Ischemic Stroke

Role: lead

NCT05074498Phase 1Completed

Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TB006 in Participants With Alzheimer's Disease

Role: lead

NCT04801056Phase 1Withdrawn

Study of TB006 in Outpatient Patients With Mild to Moderate COVID-19

Role: lead

All 7 trials loaded